+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Hypertensive Exercise Responses in Ciclosporin-Treated Normotensive Renal Transplant Recipients

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Although many patients taking ciclosporin (CS) for the long term develop hypertensive side effects, a proportion do not. We have studied the blood pressure response to graded upright bicycle exercise while continuously recording the metabolic rate in 18 normotensive renal transplant recipients whose mean age was 30.8 years (range 16–54). Nine were treated with CS alone and 9 with azathioprine and a steroid, prednisolone (AzS). Both groups performed a progressive exercise test, with work increasing by 25 W every 4 min from rest. All patients completed a workload of at least 75 W during the test. A group of 8 normal subjects whose mean age was 29 years (range 19–44) were exercised with the same protocol. The CS group had a significantly higher mean systemic blood pressure at both 50 and 75 W (124 and 132 mm Hg, respectively), compared with the AzS group (103 and 108 mm Hg; p < 0.01). The blood pressure response to exercise in the AzS group was similar to that observed in the normal group. This was despite a higher metabolic rate at each stage of work in the AzS group as compared with the CS or normal groups. Despite being normotensive at rest, renal transplant patients who are treated with CS have evidence of a vasopressor effect, with systemic vascular resistance inappropriately high for exercise, implying reduced compliance of the vascular bed.

          Related collections

          Author and article information

          S. Karger AG
          10 December 2008
          : 56
          : 2
          : 143-147
          Departments of aRespiratory Physiology, bRenal Medicine and Surgery, Addenbrooke’s Hospital, Cambridge, UK
          186122 Nephron 1990;56:143–147
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Original Paper

          Cardiovascular Medicine, Nephrology

          Ciclosporin, Hypertension, Renal transplantation, Exercise


          Comment on this article